TY - JOUR
TI - Aberrant AML1 gene expression in the diagnosis of childhood leukemias not characterized by AML1-involved cytogenetic abnormalities
AU - Adamaki, M.
AU - Vlahopoulos, S.
AU - Lambrou, G.I.
AU - Papavassiliou, A.G.
AU - Moschovi, M.
JO - Tumor Biology
PY - 2017
VL - 39
TODO - 3
SP - 1-10
PB - SAGE Publications Ltd
SN - 1010-4283, 1423-0380
TODO - 10.1177/1010428317694308
TODO - transcription factor RUNX1;  RUNX1 protein, human;  transcription factor RUNX1, acute lymphoblastic leukemia;  acute myeloid leukemia;  AML1 gene;  Article;  child;  childhood leukemia;  controlled study;  cytogenetics;  female;  gene expression;  genetic association;  human;  immunophenotyping;  informed consent;  karyotype;  limit of quantitation;  major clinical study;  male;  overall survival;  priority journal;  real time polymerase chain reaction;  acute lymphoblastic leukemia;  acute myeloid leukemia;  biosynthesis;  case control study;  genetics;  metabolism;  reverse transcription polymerase chain reaction;  survival rate;  tumor cell line, Case-Control Studies;  Cell Line, Tumor;  Child;  Core Binding Factor Alpha 2 Subunit;  Female;  Gene Expression;  Humans;  Leukemia, Myeloid, Acute;  Male;  Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Reverse Transcriptase Polymerase Chain Reaction;  Survival Rate
TODO - The AML1 (acute myeloid leukemia 1) gene, a necessary prerequisite of embryonic hematopoiesis and a critical regulator of normal hematopoietic development, is one of the most frequently mutated genes in human leukemia, involving over 50 chromosome translocations and over 20 partner genes. In the few existing studies investigating AML1 gene expression in childhood leukemias, aberrant upregulation seems to specifically associate with AML1 translocations and amplifications. The aim of this study was to determine whether overexpression also extends to other leukemic subtypes than the ones karyotypically involving AML1. We use quantitative real-time polymerase chain reaction methodology to investigate gene expression in 100 children with acute leukemias and compare them to those of healthy controls. We show that in childhood acute lymphoblastic leukemia, AML1 gene overexpression is associated with a variety of leukemic subtypes, both immunophenotypically and cytogenetically. Statistically significantly higher transcripts of the gene were detected in the acute lymphoblastic leukemia group as compared to the acute myeloid leukemia group, where AML1 overexpression appeared to associate with cytogenetic abnormalities additional to those that engage the AML1 gene, or that are reported as showing a “normal” karyotype. Collectively, our study shows that AML1 gene overexpression characterizes a broader range of leukemic subtypes than previously thought, including various maturation stages of B-cell acute lymphoblastic leukemia and cytogenetic types additional to those involving the AML1 gene. © 2017, © The Author(s) 2017.
ER -